{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-23-000044","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.049438+00:00","generated_at":"2026-06-12T03:03:33.451472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"QuidelOrtho Q2 revenue $665M, GAAP loss $(0.80)/share, adj. EPS $0.26; respiratory revenue down 74%","bullets":["Revenue $665.1M (+8% reported) but down 26% on supplemental combined basis vs Q2 2022.","GAAP diluted loss per share $(0.80); adjusted EPS $0.26 vs $2.12 supplemental combined prior year.","Non-respiratory revenue +3% supplemental combined; Labs unit +9% constant currency; respiratory -74%.","Paid down $72M on Term Loan (excess $20M) and final $40M for Alere Cardiometabolic acquisition.","Completed Savanna EUA and 510(k) FDA submissions as planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-23-000044","json":"https://secwatch.observer/filing/0001906324-23-000044.json","markdown":"https://secwatch.observer/filing/0001906324-23-000044.md","text":"https://secwatch.observer/filing/0001906324-23-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000044/0001906324-23-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000044/qdel-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:03:33.451472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7797c62229e3d0e86003e23b7c25cbc4f56685e","claim":"QuidelOrtho Corp reported the second quarter ended July 2, 2023 results: revenue $665.1 million.","evidence_excerpt":"today announced financial results for the second quarter ended July 2, 2023. The Company reported total revenue for the second quarter of 2023 of $665.1 million, compared to $613.4 million for the second quarter of 2022. GAAP diluted loss per share (LPS) for the second quarter of 2023 decreased to $(0.80), compared to diluted EPS of $0.36 for the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000044/0001906324-23-000044-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended July 2, 2023"},{"label":"Revenue","value":"$665.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}